This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Behavioral Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Quality of Life  • Rehabilitation Medicine  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Douglas E. Gladstone, MD; Kenneth W. Zamkoff, MD; Lauren Krupp, MD; Robert Peyster, MD; Patrick Sibony, MD; Christopher Christodoulou, PhD; Emily Locher, RN; Patricia K. Coyle, MD

Arch Neurol. 2006;63:1388-1393. Published online August 14, 2006 (doi:10.1001/archneur.63.10.noc60076).

Background  High-dose cyclophosphamide is active in immune-mediated illnesses.

Objective  To describe the effects of high-dose cyclophosphamide on severe refractory multiple sclerosis.

Design, Setting, and Patients  Patients with multiple sclerosis with an Expanded Disability Status Scale (EDSS) score of 3.5 or higher after 2 or more Food and Drug Administration–approved disease-modifying therapy regimens were evaluated.

Interventions  Patients received 200 mg/kg of cyclophosphamide over 4 days.

Main Outcome Measures  Patients had brain magnetic resonance imaging and neuro-ophthalmologic evaluations every 6 months and quarterly EDSS and quality-of-life evaluations for 2 years.

Results  Twelve patients were evaluated for clinical response (median follow-up, 15.0 months; follow-up range, 6-24 months). During follow-up, no patients increased their baseline EDSS scores by more than 1.0. Five patients decreased their EDSS scores by 1.0 or more (EDSS score decrease range, 1.0-5.0). Two of 11 patients had a single enhancing lesion at baseline; these lesions resolved after high-dose cyclophosphamide treatment. At 12 months, 1 patient showed 1 new enhancing lesion without a corresponding high-intensity T2-weighted or fluid-attenuated inversion recovery signal. Patients reported improvement in all of the quality-of-life parameters measured. Neurologic improvement involved changes in gait, bladder control, and visual function. Treatment response was seen regardless of the baseline presence or absence of contrast lesion activity. Patient quality-of-life improvement occurred independently of EDSS score changes. In this small group of patients with treatment-refractory multiple sclerosis, high-dose cyclophosphamide was associated with minimal morbidity and improved clinical outcomes.

Conclusions  High-dose cyclophosphamide treatment in patients with severe refractory multiple sclerosis can result in disease stabilization, improved functionality, and improved quality of life. Further studies are necessary to determine the most appropriate patients for this treatment.

Author Affiliations: Departments of Medicine (Drs Gladstone and Zamkoff and Ms Locher), Neurology (Drs Krupp, Christodoulou, and Coyle), Radiology (Dr Peyster), and Ophthalmology (Dr Sibony), State University of New York at Stony Brook.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms
Awad and Stuve
Therapeutic Advances in Neurological Disorders 2009;2:357-368.
ABSTRACT  

Optimizing Outcomes in Multiple Sclerosis - A Consensus Initiative
Coyle et al.
Mult Scler 2009;15:S5-S35.
ABSTRACT  

Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Krishnan et al.
Arch Neurol 2008;65:1044-1051.
ABSTRACT | FULL TEXT